Ketamine therapy, a beacon of hope for treatment-resistant depression, has been gaining traction, but its off-label use has raised concerns about standardization and safety. Imagine a powerful dissociative anesthetic, originally intended for battlefield use, being administered in strip mall clinics without proper monitoring or trained psychiatric support! The risk? A destabilized patient leaving traumatized instead of healed.

Enter the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3), armed with a rigorous, interdisciplinary approach using the Delphi method. This isn't your typical boardroom vote; it's an anonymous, iterative process designed to eliminate bias and ego, ensuring that guidelines reflect true expert consensus. With insights from psychiatrists, anesthesiologists, ER physicians, and psychotherapists, the new guidelines address crucial aspects like comprehensive patient evaluations, dose titration, and monitoring requirements.

These guidelines aren't just about individual safety; they're a step toward standardizing the industry, paving the way for insurance coverage and broader access. But will these new rules squeeze out clinics prioritizing profit over patient well-being? And what does this mean for the future of other emerging mental health therapies waiting in the wings?

Reference:

Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., Ko, H. S., McShane, R., Prashad, S., Santini, T., Stewart, L. H., Sullivan, P., Wolfsohn, S. D., Robinson, J. O., McGuire, A. L., & McInnes, L. A. (2026). Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). Journal of Affective Disorders, 121970. https://doi.org/10.1016/j.jad.2026.121970